NCT03369314View on ClinicalTrials.gov

Observational Study of the Use of octaplasLG®.

CompletedOBSERVATIONAL
Enrollment

263

Participants

Timeline

Start Date

March 2, 2018

Primary Completion Date

January 14, 2021

Study Completion Date

January 14, 2021

Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
DRUG

octaplasLG®

Data will be collected in all patients who have received at least one infusion of octaplasLG®

Trial Locations (14)

13385

Hôpital de la Conception, Marseille

29019

Hôpital de La Cavale Blanche, Brest

31076

Clinique Pasteur, Toulouse

37000

CHRU Bretonneau, Tours

42055

CHRU Hôpital Nord, Saint-Etienne

54511

CHU de Nancy, Vandœuvre-lès-Nancy

67347

Hospices Civils de Lyon Hôpital Edouard Herriot, Lyon

69500

Hôpital Louis Pradel, Bron

69641

Infirmerie Protestante de Lyon, Caluire-et-Cuire

75651

APHP Hopital Pitié salpêtrière, Paris

76031

CHU Hôpitaux de Rouen, Rouen

84902

CH Henri Duffaut, Avignon

92150

Hôpital Foch, Suresnes

Unknown

APHP Hopital Cochin, Paris

Sponsors

Lead Sponsor

Octapharma
All Listed Sponsors
lead

Octapharma

INDUSTRY

NCT03369314 - Observational Study of the Use of octaplasLG®. | Biotech Hunter | Biotech Hunter